摘要:
The present invention relates to 1H-Quinazoline-2,4-diones of formula (I)
wherein R 1 and R 2 are as defined in the specification, their preparation, their use as pharmaceuticals, and pharmaceutical compositions containing them. Further, intermediates for the manufacture of compounds of formula (I) are and combinations comprising compounds of formula (I) are disclosed.
摘要:
The invention relates to compounds that are amino acid derivatives, to compositions comprising the same and uses thereof for the prevention or treatment of pain, e.g. neuropathic pain, while having neutral or beneficial effect on metabolic parameters. (Formula)
摘要:
The present application describes organic compounds of a general formula: and salts, and isomers thereof, wherein R, R2 and R3 are defined in the specification. The compounds are useful for treating a gram-negative bacterial infection.
摘要:
The present invention provides α-hydroxy benzeneacetic acid derivatives of the formula as defined in the specification which is a precursor indispensable for synthesis of compounds having two 5-membered lactone rings fused to central cyclohexa-1,4-diene nucleus, and a process of easily preparing the same. According to the preparation process of the present invention, the α-hydroxy benzeneacetic acid derivative can be readily prepared at high purity and yield without using toxic materials or producing toxic by-products. Some novel compounds, synthesized by using such a α-hydroxy benzeneacetic acid derivative, have excellent fastness properties, dye fixing rate and leveling property to general synthetic fiber materials such as polyester fibers and their blends with other fibers, especially to micro fibers, and also can be used as a coloring agent for plastic resins, color tonors, color filters, etc.
摘要:
The present disclosure relates to methods of preparation of compounds resulting from the reaction of levulinic esters and epoxidized unsaturated fatty acid esters. The compounds are useful as renewable biomass-based plasticizers for a variety of polymers. Mono-, di- and tri-ketal adducts formed in a reaction between alkyl esters of levulinate and epoxidized unsaturated fatty acid esters derived from vegetable oils are also disclosed.
摘要:
There is described compounds of Formula (I), (II), (III), (IV) and (V), the salts, solvates, and hydrates thereof and pharmaceutical compositions comprising these compounds. In Formula (II), A is a ring chosen from pyridine, pyrazine, pyrimidine, imidazole, furan and thiophene. In Formula (IV), A is a ring chosen from benzene, pyridine, pyrazine, pyrimidine, imidazole, furan and thiophene (either substituted or unsubstituted) and B is a ring chosen from benzene and pyridine. The compounds of Formula (I), (II), (III), (IV) and (V) are useful in therapeutic methods and compositions for modulating and inhibiting cell proliferation, such as cancer cell proliferation, in diagnostic assays and as research tools.
摘要:
The present invention provides a pharmaceutical agent having cholesteryl ester transfer protein inhibitory action and useful as a blood lipid lowering agent and the like. The present invention relates to a compound represented by the formula wherein Ar 1 is an aromatic ring group optionally having substituents, Ar 2 is an aromatic ring group having substituents, OR'' is an optionally protected hydroxyl group, R is an acyl group, R' is a hydrogen atom or a hydrocarbon group optionally having substituents, or a salt thereof, and a pharmaceutical composition containing a compound of the formula (I) or a salt thereof or a prodrug thereof.
摘要:
A process and intermediates for the preparation of triazolopyrimidine compounds of formula I wherein R 1 , X, L 1 , L 2 , L 3 , L 4 and L 5 are as defined in the description, which comprises reacting alkyl 2-aryl-3-alkyl-3-oxopropionates of formula IV wherein R 1 and L 1 , L 2 , L 3 , L 4 and L 5 are as defined for formula I and R' represents an optionally substituted alkyl group, a) with 2-amino-[1,3,4]-triazole, and treating the resulting 5-hydroxytriazolopyrimidines of formula I, wherein X represents a hydroxy group, with a halogenating agent, and b) optionally treating the resulting 5-hydroxytriazolopyrimidines with an alcohol or a thioalkohol in the presence of a base, or with a metal amide, a metal alkyl amide or a metal dialkylamide, or a metal cyanide.